METHODS FOR IMPROVING TREATMENT OF EQUINE COLIC BY ADMINISTRATION OF A SYNTHETIC BIOENSEMBLE OR PURIFIED STRAINS THEREOF
The disclosure relates to isolated microorganisms, including novel strains of the microorganisms, synthetic bioensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, synthetic bioensembles, and compositions comprising the same, in methods for modulating the health of equine animals In particular aspects, the disclosure provides methods of treating and/or preventing colic and shifting the gut microbiome.
1 . A microbial composition comprising:
a. one or more bacteria with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-575; and
b. a carrier suitable for equine administration.
2 . The microbial composition of claim 1 , comprising one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.
3 . The microbial composition of claim 1 , comprising one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.
4 . The microbial composition of claim 1 , comprising one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476.
5 . The microbial composition of claim 1 , comprising one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476.
6 . The microbial composition of claim 1 , comprising two, three, four, five, or more bacteria with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-575.
7 . The microbial composition of claim 1 , comprising two, three, four, or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.
8 . The microbial composition of claim 1 , comprising two, three, four, or five bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.
9 . The microbial composition of claim 1 , comprising two, three, four, or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO:
142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476.
10 . The microbial composition of claim 1 , comprising two, three, four, or five bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476.
11 . A microbial composition comprising:
a. one or more bacterium selected from
i. a Clostridium spp. bacterium;
ii. a Streptococcus spp. bacterium;
iii. an Escherichia spp. bacterium;
iv. a Clostridium spp. bacterium; and
v. an Atlantibacter spp. bacterium;
b. a carrier suitable for equine administration.
12 . A microbial composition comprising:
a. one or more bacterium selected from
i. a Clostridium butyricum bacterium;
ii. a Streptococcus equinis bacterium;
iii. an Escherichia coli bacterium;
iv. a Clostridium maximum bacterium; and
v. an Atlantibacter hermannii bacterium; and
b. a carrier suitable for equine administration.
13 . The microbial composition of claim 12 , wherein:
a. the Clostridium butyricum bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of SEQ ID NOs: 5-13;
b. the Streptococcus equinis bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of SEQ ID NOs: 143-150;
c. the Escherichia coli bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of SEQ ID NOs: 321-328;
d. the Clostridium maximum bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of SEQ ID NOs: 430-437; and/or
e. the Atlantibacter hermannii bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of SEQ ID NOs: 480-486.
14 . The microbial composition of claim 12 , wherein:
a. the Clostridium butyricum bacterium comprises a 16S nucleic acid sequence comprising or consisting of one of SEQ ID NOs: 5-13;
b. the Streptococcus equinis bacterium comprises a 16S nucleic acid sequence comprising or consisting of one of SEQ ID NOs: 143-150;
c. the Escherichia coli bacterium comprises a 16S nucleic acid sequence comprising or consisting of one of SEQ ID NOs: 321-328;
d. the Clostridium maximum bacterium comprises a 16S nucleic acid sequence comprising or consisting of one of SEQ ID NOs: 430-437; and/or
e. the Atlantibacter hermannii bacterium comprises a 16S nucleic acid sequence comprising or consisting of one of SEQ ID NOs: 480-486.
15 . The microbial composition of claim 12 , wherein:
a. the Clostridium butyricum bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 5 or SEQ ID NO: 11;
b. the Streptococcus equinis bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 141 or SEQ ID NO: 142;
c. the EscheriaEscherichia coli bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 319 or SEQ ID NO: 320;
d. the Clostridium maximum bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 426 or SEQ ID NO: 433; and/or
e. the Atlantibacter hermannii bacterium comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical SEQ ID NO: 475 or SEQ ID NO: 476.
16 . The microbial composition of claim 12 , wherein:
a. the Clostridium butyricum bacterium comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 5 or SEQ ID NO: 11;
b. the Streptococcus equinis bacterium comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 141 or SEQ ID NO: 142;
c. the Escherichia coli bacterium comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 319 or SEQ ID NO: 320;
d. the Clostridium maximum bacterium comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 426 or SEQ ID NO: 433; and/or
e. the Atlantibacter hermannii bacterium comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 475 or SEQ ID NO: 476.
17 . The microbial composition of claim 1 . wherein the one or more bacteria has a MIC score of at least about 0.2.
18 . The microbial composition of claim 1 , wherein the equine is a domesticated equine or a wild equine.
19 . The microbial composition of claim 1 , wherein the equine is selected from a horse, a zebra, a mule, and a donkey.
20 . The microbial composition of claim 1 , wherein the carrier comprises a solidification agent and a sweeting agent.
21 . The microbial composition of claim 20 , wherein the solidification agent is selected from xantham gum, agar, and gelatin.
22 . The microbial composition of claim 20 , wherein the sweeting agent is selected from corn syrup, molasses, cane molasses, brewer's yeast, and honey.
23 . The microbial composition of claim 1 , wherein the composition is formulated as a gel, a liquid, a powder, a tablet, a capsule, a pill, a feed additive, a food ingredient, a food supplement, a water additive, a heat-stabilized additive, a moisture-stabilized additive, a pelleted feed additive, a pre-pelleted applied feed additive, a post-pelleted applied feed additive, or a spray additive.
24 . The microbial composition of claim 1 , wherein the composition is formulated for administration by injection, direct application to target organ, bolus administration, oral administration (such as with or as part of food), fecal enema, fecal microbiota transplant via nasogastric intubation
25 . The microbial composition of claim 1 , comprising the one or more bacteria in an amount effective to treat one or more symptoms of colic in an equine or to reduce the frequency of colic episodes.
26 . A method for preventing and/or treating colic in an equine comprising administering the microbial composition of claim 1 to an equine in need thereof in an amount effective to prevent and/or treat colic in the equine administered the microbial composition compared to an equine that was not administered the microbial composition.
27 . The method of claim 26 , wherein the equine is a domesticated equine or a wild equine.
28 . The method of claim 26 , wherein the equine is selected from a horse, a zebra, a mule, and a donkey.
29 . The method of claim 26 , wherein the microbial composition is administered daily for at least 1, 2, 3, 4, 5, 6, 7 days, or longer.
30 . The method of claim 26 , wherein the microbial composition is administered daily for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, or longer.
31 . The method of claim 26 , wherein the microbial composition is administered daily for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or longer.
32 . The method of claim 26 , wherein the microbial composition is administered to the equine with an antibiotic, a proton pump inhibitor, and/or food.
33 . The method of claim 26 , wherein the microbial composition is administered to the equine after administration of an antibiotic, a proton pump inhibitor, and/or food.
34 . The method of claim 26 , wherein the administration of the microbial composition reduces one or more symptoms of colic selected from abdominal pain, stomach irritation, rolling, kicking at stomach, distension of gastrointestinal organs, and decreased eating.
35 . The method of claim 26 , wherein the administration of the microbial composition reduces the frequency of colic episodes in an equine administered the microbial composition compared to an equine that has not been administered the microbial composition.